SM 20550

Drug Profile

SM 20550

Alternative Names: SM-20550

Latest Information Update: 01 Aug 2007

Price : $50

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Class Amidines; Anti-ischaemics; Antiarrhythmics; Cardiotonics; Indoles; Small molecules
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Ischaemic heart disorders

Most Recent Events

  • 05 Apr 2001 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 22 Mar 1999 Two preclinical studies have been added to the Ischaemic Heart Disease pharmacodynamics section ,
  • 24 Feb 1998 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top